Replies to post #253014 on Biotech Values

[DewDiligence]

PCVX seeking $1.15B* in underwritten offering:

https://www.globenewswire.com/news-release/2024/09/03/2940071/0/en/Vaxcyte-Announces-Commencement-of-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

This is a massive offering insofar as PCVX had $1.4B of net current assets at 6/30/24 (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001649094/000164909424000052/pcvx-20240630.htm ).

*Assuming exercise of underwriter’s option.

[dewophile]

I'm impressed at how quickly they were able to move forward the 31 valent program
GSK bought a program but they have yet to advance it and the 30+ still appears to be preclinical (unless they are in ultra stealth mode)
I'm not sure where PFE is w their program, and at what serotype number there starts to be serious diminishing returns (i.e. 31 might get you up to 85-90% coverage ). I honestly haven't followed the space closely, but PCVX has exceeded my expectations particularly on speed unless MRK/PFE/GSK are all tight lipped for competitive reasons